Biodesix CEO rings Nasdaq’s closing bell

LOUISVILLE — Five years to the day after taking Biodesix Inc. (Nasdaq: BDSX) public, president and CEO Scott Hutton celebrated the milestone — and the company regaining compliance with the exchange — by ringing Nasdaq’s closing bell Tuesday.

The Louisville-based company, which develops diagnostic tests for lung disease, faced delisting from Nasdaq earlier this year because its stock price had dropped below the $1 minimum for 30 days. But a one-for-20 reverse stock split in September helped the company regain compliance.

“It’s really remarkable to be here today to celebrate the anniversary of our IPO exactly five years ago today,” Hutton said as he prepared to ring the closing bell. “The last five years have been exceptionally rewarding and fulfilling for the Biodesix team, who remain committed to partnering with physicians to help those patients in dire need as they battle lung cancer. Sadly, lung cancer remains the deadliest of all cancers. More people will die of lung cancer this year than the next three cancers combined at Biodexis, we’re going to remain committed to helping physicians change that.”

Biodesix employs about 300 people, about half of them in its headquarters at 919 W. Dillon Road, an 80,000-square-foot property that formerly housed a Kohl’s store,

Biodesix is scheduled to report its third-quarter financial results Nov. 3. The company’s stock closed at $6.44 Wednesday, down 11 cents.

Share on Facebook on LinkedIn